Vertex Pharmaceuticals (VRTX) announced that Health Canada has granted Marketing Authorization for ALYFTREK, a new triple combination therapy for ...

Vertex Pharmaceuticals today announced that Health Canada has granted Marketing Authorization for PrALYFTREKTM (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for patients ...

War, what is it good for? Not much – but military conflict has historically fuelled the development of technology that’s now ...

Video webcast now available on-demand LA JOLLA, CA, July 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” ...

In recent years, the Saudi Arabian government has taken significant steps to prioritize mental health initiatives, including those specifically targeting postpartum depression. This has resulted in ...

The market for selective estrogen receptor modulators, or SERMs, is poised for considerable growth over the next decade, ...

Researchers at MIT and other institutions have identified compounds that can fight off viral infection by activating a ...

CB03-154 is a newer ALS therapy that's designed to open nerve cells' KCNQ2 and KCNQ3 potassium channels without affecting ...

AC Immune SA has synthesized new heterocyclic modulators acting as NLRP3 inflammasome inhibitors. As such, they are reported to be potentially useful for the treatment of asthma, atherosclerosis, ...

As outstanding young researchers, physicist Dr Xinyu Ma and virologist Dr Tim Krischuns are being funded through the Marie Skłodowska-Curie Actions (MSCA) and conducting research as MSCA Postdoctoral ...

Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen ...